The US FDA has approved a combination of meloxicam and rizatriptan for the acute treatment of migraine with or without aura in adults. Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID), and rizatriptan is a serotonin (5-HT) 1B/1D receptor agonist. This combination therapy offers an innovative multi-mechanistic strategy for treating migraines by targeting multiple pathways involved in a migraine attack. Clinical evidence In a clinical trial involving 1,594 migraine patients, a significantly higher number of patients who received the combination therapy significantly achieved pain freedom (19.9% vs.
6.7%) and freedom from most bothersome symptoms such as photophobia, phonophobia, and nausea (36.9% vs. 24.4%) compared to those who received a placebo two hours after administration. Notably, more patients experienced sustained pain freedom for 24 hours (16.1% vs. 5.3%).…
